logo conference-reports

Conference Reports

Key resources powered by logo MSD_HIV

HIV-Glasgow 2018 – Ibalizumab phase 3 trial: week 25 and week 48 analysis

Dr Zvi Cohen presents the phase 3 trial results of ibalizumab in heavily treatment experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen; ibalizumab was approved by the FDA in March 2018 for this patient population. Results from the Week 25 study (TMB-301) along with the Week 48 expanded access (completer) study (TMB-311) are discussed.